CD80 and neoplasm: Indeed, it has been shown that dendritic cells (DCs) that engulf tumor cells treated with recombinant TcCalr mature —represented by an increased expression of MHC II class molecules, CD80, and CD86, among other markers— in a dual canine tumor model (90).